Understanding comorbidity with depression and anxiety disorders
- PMID: 16738013
Understanding comorbidity with depression and anxiety disorders
Abstract
Comorbidity is the rule with anxiety and depressive disorders. Anxiety and major depressive disorder are often comorbid with each other; these disorders are commonly associated with other psychiatric disorders; and they are frequently found coexisting with long-standing chronic medical conditions such as cardiovascular disease and diabetes mellitus. The comorbidity of major depressive and anxiety disorders is associated with barriers to treatment and worse psychiatric outcomes, including treatment resistance, increased risk for suicide, greater chance for recurrence, and greater utilization of medical resources. Effective recognition and treatment of anxiety and depression may be associated with functional improvement in the medical disorders (eg, lower HbA1c level in patients with diabetes). Paying careful attention to the development of anxiety and depression may also positively impact the economic burden of these disorders. To help primary care physicians better understand the comorbidity of depression and anxiety and medical disorders, the authors describe three case scenarios.
Similar articles
-
Treating patients for comorbid depression, anxiety disorders, and somatic illnesses.J Am Osteopath Assoc. 2006 May;106(5 Suppl 2):S1-8. J Am Osteopath Assoc. 2006. PMID: 16738011 Review.
-
Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition.Depress Anxiety. 2007;24(3):185-95. doi: 10.1002/da.20192. Depress Anxiety. 2007. PMID: 16900465
-
Outcome and impact of mental disorders in primary care at 5 years.Psychosom Med. 2007 Apr;69(3):270-6. doi: 10.1097/PSY.0b013e3180314b59. Epub 2007 Mar 30. Psychosom Med. 2007. PMID: 17401055
-
The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.Depress Anxiety. 2008;25(2):91-7. doi: 10.1002/da.20279. Depress Anxiety. 2008. PMID: 17311265
-
Unraveling the diagnostic clues of depression and GAD: the primary care challenge.Psychopharmacol Bull. 2002 Summer;36 Suppl 2:150-7. Psychopharmacol Bull. 2002. PMID: 12490831 Review.
Cited by
-
Correlation of Anxiety and Depression to the Development of Gastroesophageal Disease in the Younger Population.Cureus. 2022 Dec 19;14(12):e32712. doi: 10.7759/cureus.32712. eCollection 2022 Dec. Cureus. 2022. PMID: 36686114 Free PMC article. Review.
-
Zebrafish, a biological model for pharmaceutical research for the management of anxiety.Mol Biol Rep. 2023 Apr;50(4):3863-3872. doi: 10.1007/s11033-023-08263-1. Epub 2023 Feb 9. Mol Biol Rep. 2023. PMID: 36757551 Review.
-
Measuring religiosity/spirituality in diverse religious groups: a consideration of methods.J Relig Health. 2011 Dec;50(4):841-51. doi: 10.1007/s10943-011-9457-9. J Relig Health. 2011. PMID: 21246279
-
Supplemental dietary choline during development exerts antidepressant-like effects in adult female rats.Brain Res. 2012 Mar 14;1443:52-63. doi: 10.1016/j.brainres.2012.01.018. Epub 2012 Jan 17. Brain Res. 2012. PMID: 22305146 Free PMC article.
-
Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):685-95. doi: 10.1007/s00210-013-0867-y. Epub 2013 Apr 16. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23584634